EV / EBITDA společnosti Edesa Biotech
Jaká je hodnota metriky EV / EBITDA společnosti Edesa Biotech?
Hodnota metriky EV / EBITDA společnosti Edesa Biotech, Inc. je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Edesa Biotech
Čemu se věnuje společnost Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Firmy s metrikou ev / ebitda podobnou společnosti Edesa Biotech
- Hodnota metriky EV / EBITDA společnosti Bambuser AB (publ) je N/A
- Hodnota metriky EV / EBITDA společnosti Nevada Metals je N/A
- Hodnota metriky EV / EBITDA společnosti Elys Game Technology je N/A
- Hodnota metriky EV / EBITDA společnosti Velodyne Lidar je N/A
- Hodnota metriky EV / EBITDA společnosti Blue Sky Alternative Investments je N/A
- Hodnota metriky EV / EBITDA společnosti Arix Bioscience plc je N/A
- Hodnota metriky EV / EBITDA společnosti Edesa Biotech je N/A
- Hodnota metriky EV / EBITDA společnosti Shenzhen Neptunus Interlong Bio-technique je N/A
- Hodnota metriky EV / EBITDA společnosti Baumot AG je N/A
- Hodnota metriky EV / EBITDA společnosti Discovery Harbour Resources je N/A
- Hodnota metriky EV / EBITDA společnosti Guardion Health Sciences Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Taronis Fuels je N/A
- Hodnota metriky EV / EBITDA společnosti DQ Entertainment (International) je N/A